

DAFTAR PUSTAKA

- Abelson, B. *et al.* (2018) 'Sex differences in lower urinary tract biology and physiology', *Biology of Sex Differences*, 9(1), pp. 1–13. Available at: <https://doi.org/10.1186/s13293-018-0204-8>.
- Beysens, M. and Tailly, T.O. (2018) 'Ureteral stents in urolithiasis', *Asian Journal of Urology*, 5(4), pp. 274–286. Available at: <https://doi.org/10.1016/j.ajur.2018.07.002>.
- Bolla, S.R., Odeluga, N. and Jetti, R. (2020) *Histology, Bladder, StatPearls*. Available at: <https://doi.org/31082007>.
- Buhmann, M.T. *et al.* (2019) 'Encrustations on ureteral stents from patients without urinary tract infection reveal distinct urotypes and a low bacterial load', *Microbiome*, 7(1), p. 60. Available at: <https://doi.org/10.1186/s40168-019-0674-x>.
- Camtosun, A. and Bicer, S. (2020) 'The impact of Double J stent on the quality of sexual life and job performance', *Clinical and Experimental Obstetrics and Gynecology*, 47(2), pp. 199–201. Available at: <https://doi.org/10.31083/j.ceog.2020.02.5064>.
- Chai, T.C., Russo, A. and Lu, M. (2016) 'Mucosal signaling in the bladder', *Autonomic Neuroscience: Basic and Clinical*, 200, pp. 49–56. Available at: <https://doi.org/10.1016/j.autneu.2015.08.009>.
- Ciayadi, T.A. *et al.* (2023) 'A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms', *Pan African Medical Journal*, 46. Available at: <https://doi.org/10.11604/pamj.2023.46.2.38100>.
- Dellis, A.E., Keeley, F.X. Jr., Manolas, V., Skolarikos, A.A. (2014). *Role of α -blockers in the treatment of ureteral stent-related symptoms: a prospective randomized control study*. *Urology*, **83**(1):56–62.
- Delnay, K.M. *et al.* (1999) 'Bladder histological changes associated with chronic indwelling urinary catheter.', *The Journal of urology*, 161(4), pp. 1106–8; discussion 1108–9.
- Fischer, K.M., Louie, M. and Mucksavage, P. (2018) 'Ureteral Stent Discomfort and Its Management', *Current Urology Reports*, 19(8), pp. 5–8. Available at: <https://doi.org/10.1007/s11934-018-0818-8>.
- Giannarini, G. *et al.* (2011) 'Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire', *BJU International*, 107(4), pp. 648–654. Available at: <https://doi.org/10.1111/j.1464-410X.2010.09482.x>.
- Gibson, W. *et al.* (2017) 'Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study', *European Urology Focus*, 3(6), pp. 629–638. Available at: <https://doi.org/10.1016/j.euf.2017.08.008>.
- Hasbi, B.E. *et al.* (2021) 'The Effectiveness Between Tamsulosin and Solifenacin Combined with Tamsulosin on Treatment of Ureteral Stent-Related Symptoms'. Available at: <https://doi.org/10.20956/nmsj.v6i1.1>.

- Janssen, C. *et al.* (2017) 'A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis', *Urology*, 104, pp. 242.e1-242.e8. Available at: <https://doi.org/10.1016/j.urology.2017.01.029>.
- Joshi, H.B., Newns, N.R., Stainthorpe, A., MacDonagh, R.P., Keeley, F., Timoney, A.G. (2003). *Ureteral stent symptom questionnaire: development and validation of a questionnaire to assess ureteral stent-related symptoms*. *Urology*, **61**(2):3–7.
- Keay, S.K., Birder, L.A. and Chai, T.C. (2014) 'Evidence for bladder urothelial pathophysiology in functional bladder disorders', *BioMed Research International*, 2014. Available at: <https://doi.org/10.1155/2014/865463>.
- Kelleher, C. *et al.* (2018) 'Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis [Figure presented]', *European Urology*, 74(3), pp. 324–333. Available at: <https://doi.org/10.1016/j.eururo.2018.03.020>.
- Lee, S.-W. *et al.* (2018) 'Lower urinary tract symptoms associated with double-J stent', *Urological Science* [Preprint]. Available at: https://doi.org/10.4103/UROS.UROS_56_18.
- Nachawati, D. and Patel, J. (2021) 'Alpha Blockers', *Encyclopedia of Toxicology: Third Edition* [Preprint].
- Navanimitkul, N. and Lojanapiwat, B. (2010) 'Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: A randomized controlled study', *Journal of International Medical Research*, 38(4), pp. 1436–1441. Available at: <https://doi.org/10.1177/147323001003800425>.
- Parsons, L. *et al.* (1990) 'Bladder Surface Glycosaminoglycans: An Epithelial Permeability Barrier', *Journal of Urology*, 143(1), pp. 139–142. Available at: [https://doi.org/10.1016/S0022-5347\(17\)39897-X](https://doi.org/10.1016/S0022-5347(17)39897-X).
- Patil SR, Negi KK, Patil SB, Kundargi VS (2025). *Mirabegron versus tamsulosin in reducing double-J stent-related symptoms: a prospective comparative study*. *Cureus*, 17(9):e91925.
- Pratiwi, J.D., Syahrir, S., Hamid, F., Faruk, M., Palinrungi, M.A. (2026). *Effectiveness of tamsulosin administration on the degree of bladder mucosal inflammation in patients following ureteral stent placement: a randomized controlled trial*. *Chirurgia (Turin)*, **39**(1):14–20.
- Rizki DA, Safriadi F, Noegroho BS (2020). *Effects of tamsulosin 0.2 mg and 0.4 mg on lower urinary tract symptom score of USSQ in patients with indwelling DJ stents*. *Indonesian Journal of Urology*, 27(2):163–169.
- Robinson, D. and Cardozo, L. (2009) 'Solifenacin: pharmacology and clinical efficacy', *Expert Review of Clinical Pharmacology*, 2(3), pp. 239–253. Available at: <https://doi.org/10.1586/ecp.09.3>.
- Sellers, D., Chess-Williams, R. and Michel, M.C. (2018) 'Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium', *Naunyn-Schmiedeberg's Archives of Pharmacology*, 391(7), pp. 675–694. Available at: <https://doi.org/10.1007/s00210-018-1510-8>.

- Singh, R., Bhangu, G.S., Bansal, D., Rattan, A. (2020). *Effect of tamsulosin on ureteric stent-related morbidity: a double-blind randomized placebo-controlled study*. International Surgery Journal, **8**(1):294–299.
- Tae, B.S. *et al.* (2018) ‘Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study’, *BJU International*, **122**(5), pp. 866–872. Available at: <https://doi.org/10.1111/bju.14416>.
- Vogt, B. and Chokri, I. (2020) ‘Histological Inflammation in Human Ureter either Healthy or Fitted with Double-Pigtail Stent or a Thin 0.3 F Suture Thread: A Preliminary Study’, *Advances in Urology*, 2020. Available at: <https://doi.org/10.1155/2020/1204897>.
- Wang, G. and McKenney, J.K. (2019) ‘Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update’, *Archives of Pathology & Laboratory Medicine*, **143**(5), pp. 571–577. Available at: <https://doi.org/10.5858/arpa.2017-0539-RA>.
- Zhang, J., Wang, D., Chi, J., Lou, K., Wu, J., Cui, Y. (2025). *A systematic review and meta-analysis of the efficacy and safety of mirabegron vs. tamsulosin in alleviating double-J catheter related symptoms*. Frontiers in Medicine (Nephrology), **12**.
- Zhou, L. *et al.* (2015) ‘Effects of α -Blockers, Antimuscarinics, or Combination Therapy in Relieving Ureteral Stent-Related Symptoms: A Meta-Analysis’, *Journal of Endourology*, **29**(6), pp. 650–656. Available at: <https://doi.org/10.1089/end.2014.0715>.